4.8 Article

Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

期刊

CIRCULATION
卷 126, 期 19, 页码 2309-2316

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.112.101808

关键词

atrial fibrillation; outcomes assessment; quality improvement; warfarin

资金

  1. Boehringer-Ingelheim
  2. McMaster University Department of Medicine Internal Career Research Award
  3. AstraZeneca
  4. Merck/Schering-Plough
  5. Bristol-Myers Squibb/Pfizer
  6. GlaxoSmithKline
  7. Regado Biosciences
  8. Evolva
  9. Protola
  10. C.S.L. Behring
  11. Athera Biotechnologies
  12. Schering-Plough
  13. Bayer
  14. Corgenix Medical Corporation
  15. Sanofi-Aventis
  16. Dade-Behring
  17. Aryx Therapeutics
  18. Bristol Myers Squibb
  19. Pfizer
  20. Eisai
  21. Merck
  22. Diachi Sanko
  23. Gilead
  24. Johnson Johnson
  25. Janssen Scientific Affairs
  26. Medtronics
  27. Portola Pharmaceuticals
  28. Pozen Inc

向作者/读者索取更多资源

Background-The outcome of atrial fibrillation patients on warfarin partially depends on maintaining adequate time in therapeutic International Normalized Ratio range (TTR). Large differences in TTR have been reported between centers and countries. The association between warfarin dosing practice, TTR, and clinical outcomes was evaluated in Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial patients receiving warfarin. Methods and Results-RE-LY provided an algorithm for warfarin dosing, recommending no change for in-range, and 10% to 15% weekly dose changes for out-of-range International Normalized Ratio values. We determined whether dose adjustments were consistent with algorithm recommendations but could not verify whether providers used the algorithm. Using multilevel regression models to adjust for patient, center, and country characteristics, we assessed whether algorithm-consistent warfarin dosing could predict patient TTR and the composite outcome of stroke, systemic embolism, or major hemorrhage. We included 6022 nonvalvular atrial fibrillation patients from 912 centers in 44 countries. We found a strong association between the proportion of algorithm-consistent warfarin doses and mean country TTR (R-2 = 0.65). The degree of algorithm-consistency accounted for 87% of the between-center and 55% of the between-country TTR variation. Each 10% increase in center algorithm-consistent dosing independently predicted a 6.12% increase in TTR (95% confidence interval, 5.65-6.59) and an 8% decrease in rate of the composite clinical outcome (hazard ratio, 0.92; 95% confidence interval, 0.85-1.00). Conclusions-Adherence, intentional or not, to a simple warfarin dosing algorithm predicts improved TTR and accounts for considerable TTR variation between centers and countries. Systems facilitating algorithm-based warfarin dosing could optimize anticoagulation quality and improve clinical outcomes in atrial fibrillation on a global scale. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600. (Circulation. 2012; 126: 2309-2316.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据